Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

AstraZeneca pays $2.5bn, plus earn-outs, for majority stake in Acerta Pharma

Executive Summary

AstraZeneca PLC is further strengthening its blood cancer assets by acquiring a 55% stake in three-year-old private biopharma Acerta Pharma BV. Total consideration for the initial stake is $4bn, with $2.5bn payable up front and the remainder within the next three years.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Includes Earnout
    • Partial Acquisition
    • Payment Includes Cash

Related Companies